HIV protease inhibitors reduce IL-2 release from normal human phytohaemagglutinin-activated T cells.
Lucia
M B
MB
Rutella
S
S
Leone
G
G
Cauda
R
R
D002121:Calcium Channel Blockers / Q000494:pharmacology; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D006801:Humans; D019469:Indinavir / Q000494:pharmacology*; D007376:Interleukin-2 / Q000096:biosynthesis*; D008213:Lymphocyte Activation; D008934:Mitogens / Q000494:pharmacology; D010835:Phytohemagglutinins / Q000494:pharmacology; D019438:Ritonavir / Q000494:pharmacology*; D019258:Saquinavir / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D014700:Verapamil / Q000494:pharmacology
D002121:Calcium Channel Blockers; D017320:HIV Protease Inhibitors; D007376:Interleukin-2; D008934:Mitogens; D010835:Phytohemagglutinins; D019469:Indinavir; D014700:Verapamil; D019258:Saquinavir; D019438:Ritonavir